Hacettepe University, Faculty of Medicine, Department of Radiation Oncology, Ankara, Turkey.
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e263-8. doi: 10.1016/j.ijrobp.2011.02.054. Epub 2011 Apr 22.
We assessed therapeutic outcomes of reirradiation with robotic stereotactic radiotherapy (SBRT) for locally recurrent nasopharyngeal carcinoma (LRNPC) patients and compared those results with three-dimensional conformal radiotherapy (CRT) with or without brachytherapy (BRT).
Treatment outcomes were evaluated retrospectively in 51 LRNPC patients receiving either robotic SBRT (24 patients) or CRT with or without BRT (27 patients) in our department. CRT was delivered with a 6-MV linear accelerator, and a median total reirradiation dose of 57 Gy in 2 Gy/day was given. Robotic SBRT was delivered with CyberKnife (Accuray, Sunnyvale, CA). Patients in the SBRT arm received 30 Gy over 5 consecutive days. We calculated actuarial local control and cancer-specific survival rates for the comparison of treatment outcomes in SBRT and CRT arms. The Common Terminology Criteria for Adverse Events v3.0 was used for toxicity evaluation.
The median follow-up was 24 months for all patients. Two-year actuarial local control rates were 82% and 80% for SBRT and CRT arms, respectively (p = 0.6). Two-year cancer-specific survival rates were 64% and 47% for the SBRT and CRT arms, respectively (p = 0.4). Serious late toxicities (Grade 3 and above) were observed in 21% of patients in the SBRT arm, whereas 48% of patients had serious toxicity in the CRT arm (p = 0.04). Fatal complications occurred in three patients (12.5%) of the SBRT arm, and four patients (14.8%) of the CRT arm (p = 0.8). T stage at recurrence was the only independent predictor for local control and survival.
Our robotic SBRT protocol seems to be feasible and less toxic in terms of late effects compared with CRT arm for the reirradiation of LRNPC patients.
我们评估了机器人立体定向放射治疗(SBRT)对局部复发性鼻咽癌(LRNPC)患者的治疗效果,并将这些结果与三维适形放疗(CRT)联合或不联合近距离放疗(BRT)进行比较。
我们对 51 例在我科接受机器人 SBRT(24 例)或 CRT 联合或不联合 BRT(27 例)治疗的 LRNPC 患者进行了回顾性疗效评估。CRT 采用 6MV 直线加速器,总再照射剂量中位数为 57Gy,每天 2Gy。机器人 SBRT 采用 CyberKnife(Accuray,加利福尼亚州森尼韦尔)。SBRT 组患者接受 30Gy,连续 5 天。我们计算了 SBRT 和 CRT 组的局部控制和癌症特异性生存率的累积率,以比较治疗结果。采用不良事件通用术语标准 3.0 进行毒性评估。
所有患者的中位随访时间为 24 个月。SBRT 和 CRT 组的 2 年局部控制率分别为 82%和 80%(p=0.6)。SBRT 和 CRT 组的 2 年癌症特异性生存率分别为 64%和 47%(p=0.4)。SBRT 组有 21%的患者出现严重迟发性毒性(3 级及以上),而 CRT 组有 48%的患者出现严重毒性(p=0.04)。SBRT 组有 3 例(12.5%)患者发生致命并发症,CRT 组有 4 例(14.8%)患者发生致命并发症(p=0.8)。复发时的 T 分期是局部控制和生存的唯一独立预测因素。
与 CRT 组相比,我们的机器人 SBRT 方案似乎在局部复发 LRNPC 患者的再照射方面具有可行性,且晚期毒性更小。